

Interim report of
MEDICLIN Aktiengesellschaft
for the period from 1 January 2023 to 30 September 2023

MEDICLIN: Key data on business development

	9M 2023	9M 2022
Number of shares in millions	47.5	47.5
Number of cases (inpatient)	81,685	78,495
Number of beds as of 30.09.	8,132	8,315
Occupancy rate in %	84.5	78.5
Number of full-time employees (average number)	7,014	7,014

In thousands of €	9M 2023	9M 2022
Cash flow from operating activities	49,858	34,540
Cash flow from operating activities per share in €	1.05	0.73
Sales	547,136	526,329
EBITDA	68,246	65,183
EBITDA margin in %	12.5	12.4
EBIT (operating result)	29,385	10,088
EBIT margin in %	5.4	1.9
Financial result	-15,944	-5,752
Total consolidated result	15,228	4,439
Earnings per share in €	0.32	0.09
Gross capital expenditure	25,958	17,638
Thereof subsidies	6,373	5,823
Interest coverage factor (EBITDA / interest result)	4.3x	11.3x

In thousands of €	30.09.2023	31.12.2022
Balance sheet total	911,977	916,112
Equity	226,313	209,323
Equity ratio in %	24.8	22.8
Return on equity ¹ in %	9.1	4.6
Financial liabilities (to banks)	93,377	94,313
Cash and cash equivalents	109,642	88,039
Net financial debt ²	25,828	30,832
Net financial debt ² / EBITDA ³	0.3x	0.4x

¹ Total consolidated result in the last 12 months / equity

² Adjusted average net financial debt in the last four quarters

³ Adjusted EBITDA in the last 12 months

Due to arithmetical reasons, calculation differences of +/- one unit (€, % etc.) may occur; percentage rates and changes in % were calculated on the basis of non-rounded € values.

Report on the economic position for the first nine months of 2023

General statement on results of operations, financial position and net assets

Occupancy rate continues upwards trend, especially in the post-acute segment

A rising occupancy rate with relation to medical, therapeutic and nursing care services led to sales and earnings growth within the Group. In the first nine months of the current financial year, the number of inpatients treated rose by 4.1 % to 81,685 patients, while the occupancy rate rose by 6.0 percentage points to 84.5 % compared to the prior-year period.

Results of operations

Group sales in the first nine months of 2023 amounted to EUR 547.1 mill., thus exceeding the prior-year figure (EUR 526.3 mill.) by 4.0 % or EUR 20.8 mill. Adjusted for benefits under the protective shield to manage the COVID-19 pandemic and divestments, Group sales even rose by EUR 43.0 mill. or 8.7 % compared to the previous year.

The Group operating result was EUR 29.4 mill. in the period under review and was thus approximately EUR 19.3 mill. higher than the prior-year figure of EUR 10.1 mill. A clinic closure as well as an increase in the cost of materials and higher personnel costs had a negative impact on the Group's operating result. The cost of materials increased by EUR 5.2 mill. compared to the previous year. The Group's personnel expenses rose by EUR 19.9 mill. compared to the previous year.

Financial position and net assets

MEDICLIN's capital expenditure in the first nine months of 2023 totalled EUR 24.9 mill. for tangible and intangible assets (previous year: EUR 17.5 mill.). Cash and cash equivalents amounted to EUR 109.6 mill. as of 30 September 2023 (31.12.2022: EUR 92.3 mill.). Cash and cash equivalents include benefits under the protective shield amounting to EUR 22.5 mill. that will likely have to be repaid in the current year.

Effective on 30 April 2023, Dr. Hoefer-Janker GmbH & Co. Klinik KG and MVZ MediClin Bonn GmbH were disposed of by way of a share deal. The effects of these transactions on the balance sheet as well as the off-balance sheet effects are presented on page 23 of the interim report for the first six months of 2023 available on the MEDICLIN website at <https://www.mediclin.de/en/investor-relations/financial-publications/>. There was no need to recognise an impairment of the fair value.

The Management Board rates both the results of operations and the Group's financial position and net assets as sound.

Outlook 2023 – EBIT forecast to be at the lower end of the guidance/sales guidance confirmed

Based on the business performance in the third quarter and the first nine months of the year, the MEDICLIN Management Board now assumes that MEDICLIN will reach EBIT at the lower end of the forecast. The Management Board thus expects EBIT amounting to EUR 36 to 38 mill. in the 2023 financial year. The forecast for the Group's sales development (+3.0 % to +4.0 % growth over the previous year) was confirmed. Assuming that the sector environment remains unchanged, MEDICLIN is thus well on its way to reaching the forecasts for the 2023 financial year as issued in the Annual Report 2022.

Results of operation, financial position and net assets

Results of operation

Group sales in the first nine months of 2023 were up on the previous year's value, increasing by EUR 20.8 mill. or 4.0 %, respectively.

SALES AND EARNINGS PERFORMANCE OF THE GROUP

	9M 2023	9M 2022
Group sales in millions of €	547.1	526.3
Raw materials and consumables used in millions of €	104.3	99.1
Cost of materials ratio in %	19.1	18.8
Staff costs in millions of €	347.2	327.3
Staff costs ratio in %	63.5	62.2
Depreciation and amortisation in millions of €	38.9	55.1
Other operating expenses in millions of €	49.5	44.3
Group operating result in millions of €	29.4	10.1

Compared to the same period last year, raw materials and consumables used rose by EUR 5.2 mill. (+5.2 %) to EUR 104.3 mill. The largest increase amounting to EUR 6.5 mill. refers to the cost of external medical staff within the cost of purchased services, which increased by the factor of 2.5 compared with the same period of the previous year, thus amounting to EUR 11.0 mill. in the period under review. Given energy cost allowances received and lower prices on the energy markets, energy costs decreased considerably compared to the previous year. They amounted to EUR 11.9 mill. in the period under review, down from EUR 14.3 mill. in the prior-year period. Staff costs rose by EUR 19.9 mill. (+6.1 %) to EUR 347.2 mill., mainly due to salary increases. Other operating expenses increased by EUR 5.2 mill.

Depreciation and amortisation decreased by EUR 16.2 mill. The main reason for the decrease (EUR –15.4 mill.) is the new conditions negotiated in November 2022 for the rental contracts for clinics.

The renegotiated rental contracts and the requirements under IFRS 16 led to a clearly negative financial result of EUR –15.9 mill. that was EUR 10.2 mill. below the prior-year level. Lease liabilities as per IFRS 16 account for EUR 14.4 mill. (9M 2022: EUR 4.6 mill.) of the interest expenses totalling EUR 17.8 mill. (9M 2022: EUR 6.3 mill.).

The Group operating result improved by EUR 19.3 mill. to EUR 29.4 mill.

The total consolidated result attributable to shareholders of MEDICLIN Aktiengesellschaft was EUR 15.3 mill. (9M 2022: EUR 4.4 mill.). Earnings per share came to EUR 0.32 (9M 2022: EUR 0.09).

The sales and earnings performance at segment level is illustrated in detail in the segment reporting section.

Financial position and net assets

The cash flow from operating activities of EUR 49.9 mill. in the first nine months of 2023 clearly exceeded the prior-year level of EUR 34.5 mill. The EUR 15.4 mill. increase is mainly attributable to the rise in total consolidated result, which, at EUR 15.3 mill., was EUR 10.9 mill. higher than in the previous year (9M 2022: EUR 4.4 mill.).

Payments received from investment subsidies totalled EUR 17.8 mill. (previous year: EUR 14.7 mill.). MEDICLIN expended a total of EUR 24.9 mill. on tangible and intangible assets (previous year: EUR 17.5 mill.). Adjusted for proceeds from divestments amounting to EUR 9.5 mill., the cash flow from investing activities amounted to EUR 2.5 mill., up from EUR –2.5 mill. in the previous year.

Due to the renegotiated rental contracts and the resulting positive effects under IFRS 16, the cash flow from financing activities (EUR –34.1 mill.) has improved over the previous year (EUR –41.9 mill.).

All in all, the cash flow for the period is EUR 17.4 mill. (previous year: EUR –9.9 mill.), taking cash and cash equivalents at the end of the period up to EUR 109.6 mill. which is on par with the prior year level (30.09.2022: EUR 110.2 mill.). Cash and cash equivalents include benefits under the protective shield amounting to EUR 22.5 mill. that will likely have to be repaid in the current year.

LIQUIDITY

In millions of €	9M 2023	9M 2022
Cash flow from operating activities	49.9	34.5
Thereof total consolidated result	15.2	4.4
Cash flow from investing activities	2.5	–2.5
Cash flow from financing activities	–34.1	–41.9
Change in consolidation scopes for financial funds	–0.9	0
Cash flow for the period	17.4	–9.9
Cash and cash equivalents at the beginning of the period	92.2	120.1
Cash and cash equivalents at the end of the period	109.6	110.2

Except for the increase in the equity ratio from 22.8 % to 24.8 %, the balance sheet as at 30 September 2023 shows no significant changes on either side compared to 31 December 2022.

BALANCE SHEET STRUCTURE

In millions of €	30.09.2023	In % of balance sheet total	31.12.2022	In % of balance sheet total
Assets				
Non-current assets	624.3	68.5	654.1	71.4
Current assets	287.7	31.5	262.0	28.6
	912.0	100.0	916.1	100.0
Equity and liabilities				
Equity	226.3	24.8	209.3	22.8
Non-current liabilities	516.6	56.7	535.9	58.5
Current liabilities	169.1	18.5	170.9	18.7
	912.0	100.0	916.1	100.0

Employees

The average number of full-time employees remained unchanged versus the prior-year period. All in all, an average of 9,962 employees (9M 2022: 10,096) worked for the Group in the first nine months of the current financial year.

On average, the Group employed 367 trainees in the reporting period (9M 2022: 377 trainees).

AVERAGE NUMBER OF EMPLOYEES IN THE GROUP AND IN THE SEGMENTS

Shown in full-time employees	9M 2023	9M 2022	Change
Post-acute	3,643	3,749	-106
Acute	2,022	2,031	-9
Other activities	1,349	1,234	+115
Thereof nursing care business area	201	211	-10
Thereof service business area (including administration)	1,148	1,023	+125
Group	7,014	7,014	0

Segment reporting

In the segment post-acute, sales rose by EUR 13.6 mill. (+4.2 %) year-on-year. Adjusted for one-off and extraordinary effects (benefits under the protective shield/desinvestment), segment sales rose by EUR 24.9 mill. or 8.1 %. Compared to the previous year, the acute segment showed an increase in segment sales of EUR 4.4 mill. (+2.3%). Adjusted for one-off and extraordinary effects (benefits under the protective shield/desinvestment), segment sales rose by EUR 14.4 mill. (+8.3 %). In the other activities segment, sales of the nursing care business area (EUR 15.8 mill.) improved by EUR 1.9 mill. or 13.2 % compared with the same period of the previous year. In the prior-year period, this figure still included EUR 1.0 mill. in benefits received under the protective shield to manage the COVID-19 pandemic.

SALES

In millions of €	9M 2023	9M 2022	Change in %
Post-acute	337.0	323.4	+4.2
Acute	191.8	187.4	+2.3
Other activities and reconciliation	18.3	15.5	+18.3
Thereof nursing care business area	15.8	13.9	+13.2
Group	547.1	526.3	+4.0

RAW MATERIALS AND CONSUMABLES USED

	9M 2023	9M 2022	Change in %
Post-acute			
Raw materials and consumables used in millions of €	67.6	63.4	+6.7
Cost of materials ratio in %	20.1	19.6	
Acute			
Raw materials and consumables used in millions of €	57.3	52.2	+9.9
Cost of materials ratio in %	29.9	27.8	

STAFF COSTS

	9M 2023	9M 2022	Change in %
Post-acute			
Staff costs in millions of €	179.3	173.1	+3.5
Staff costs ratio in %	53.2	53.5	
Acute			
Staff costs in millions of €	116.1	110.8	+4.8
Staff costs ratio in %	60.5	59.1	

SEGMENT RESULT

In millions of €	9M 2023	9M 2022
Post-acute	35.1	14.3
Acute	-5.4	-6.9
Other activities and reconciliation	-0.3	2.7
Group	29.4	10.1

Forward-looking statements

This report contains forward-looking statements that are based on management's current expectations. Words such as "anticipate", "assume", "believe", "estimate", "expect", "intend", "can/could", "may", "might", "plan", "project", "should" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties that are based on the current assumptions and forecasts of MEDICLIN AG's management. Should any of these risks and uncertainties materialise, or if the assumptions underlying any of the forward-looking statements prove incorrect, then the actual results may be materially different from those expressed or implied by such statements. MEDICLIN AG does not intend or assume any obligation to continuously update these forward-looking statements, so as to adapt them to events or developments that occur after the release of this interim report.

Consolidated interim balance sheet as of 30 September 2023

ASSETS

in €	30.09.2023	31.12.2022
NON-CURRENT ASSETS		
Goodwill and other intangible assets		
Concessions, licences	4,986,790	4,173,149
Goodwill	49,813,841	49,868,841
Payments on account	967,529	1,492,772
	55,768,160	55,534,762
Property, plant and equipment		
Land, land rights and buildings including buildings on third-party land	115,747,319	121,669,374
Right-of-use assets on land, land rights and buildings incl. buildings on third-party land	347,290,503	366,977,343
Technical equipment and machines	10,063,526	10,887,098
Operating and office equipment	28,678,809	29,791,750
Right-of-use assets on operating and office equipment	1,827,253	1,820,387
Payments on account and assets under construction	21,310,890	12,792,886
	524,918,300	543,938,838
Financial assets		
Investment in stock of subsidiaries	64,822	64,822
Reinsurance cover	717,127	720,713
Other financial investments	2,056	2,056
	784,005	787,591
Other assets		
Receivables pursuant to hospital financing law	31,948,180	43,355,330
	31,948,180	43,355,330
Deferred tax assets	10,919,299	10,487,180
	624,337,944	654,103,701
CURRENT ASSETS		
Inventories	8,275,671	8,869,473
Trade receivables	97,672,962	88,489,268
Current income tax claims	0	1,400,513
Other financial assets		
Receivables pursuant to Hospital Compensation Act (KHEntgG) / Federal Directive on Nursing Care Rates (BPfIV)	42,680,820	37,952,706
Other current financial assets	8,268,892	10,266,898
	50,949,712	48,219,604
Other assets		
Prepaid expenses	4,756,963	1,462,951
Receivables pursuant to hospital financial law	16,342,279	11,911,941
	21,099,242	13,374,892
Cash and cash equivalents	109,641,945	88,039,485
Assets held for sale	0	13,615,035
	287,639,532	262,008,270
	911,977,476	916,111,971

EQUITY AND LIABILITIES

in €	30.09.2023	31.12.2022
EQUITY		
Share of MEDICLIN Group		
Subscribed capital	47,500,000	47,500,000
Capital reserve	129,391,829	129,391,829
Revenue reserve	39,654,329	37,906,157
Consolidated balance sheet result	9,682,751	-5,591,162
	226,228,909	209,206,824
Non-controlling interests	84,037	115,976
	226,312,946	209,322,800
NON-CURRENT LIABILITIES		
Financial liabilities		
Liabilities to banks	66,745,715	67,542,434
	66,745,715	67,542,434
Lease liabilities	368,855,228	384,947,721
Pensions and similar commitments	37,936,374	40,228,069
Other provisions	2,438,635	2,451,304
Other payables		
Liabilities pursuant to hospital financing law	38,987,006	39,164,889
Miscellaneous payables	1,653,375	1,611,651
	40,640,381	40,776,540
	516,616,333	535,946,068
CURRENT LIABILITIES		
Trade payables	10,253,827	14,495,203
Financial liabilities		
Liabilities to banks	26,631,494	26,770,232
	26,631,494	26,770,232
Lease liabilities	23,909,491	23,410,612
Other provisions	12,839,931	12,605,537
Current income tax liabilities	786,376	0
Other financial liabilities		
Liabilities pursuant to Hospital Compensation Act (KHEntgG) / Federal Directive on Nursing Care Rates (BPfIV)	5,908,492	4,664,881
Miscellaneous financial liabilities	6,651,530	5,356,688
	12,560,022	10,021,569
Other payables		
Liabilities pursuant to hospital financing law	26,649,283	27,805,814
Miscellaneous payables	55,417,773	53,189,317
	82,067,056	80,995,131
Liabilities in connection with assets held for sale	0	2,544,819
	169,048,197	170,843,103
	911,977,476	916,111,971

Consolidated interim profit and loss account

in €	Jan. – Sept. 2023	Jan. – Sept. 2022
Sales	547,135,857	526,329,482
Other operating income	22,162,013	9,585,129
Total operating performance	569,297,870	535,914,611
Raw materials and consumables used		
a) Cost of raw materials and supplies	–62,533,751	–57,843,983
b) Cost of purchased services	–41,782,380	–41,285,535
	–104,316,131	–99,129,518
Staff costs		
a) Wages and salaries	–292,873,288	–276,480,212
b) Social security, pension and retirement	–54,323,497	–50,860,005
	–347,196,785	–327,340,217
Other operating expenses	–49,539,377	–44,262,318
Result before interest, taxes, depreciation and amortisation / EBITDA	68,245,577	65,182,558
Depreciation and amortisation	–38,860,782	–55,094,780
Operating result / EBIT	29,384,795	10,087,778
Financial result		
a) Income from participations	0	0
b) Interest and similar income	1,898,693	577,518
c) Interest and similar expenses	–17,842,761	–6,329,393
	–15,944,068	–5,751,875
Result before tax	13,440,727	4,335,903
Taxes on income	1,787,248	103,244
Total consolidated result	15,227,975	4,439,147
Thereof attributable to shareholders of MEDICLIN AG	15,273,913	4,350,213
Thereof attributable to non-controlling interests	–45,938	88,934
Total consolidated result attributable to shareholders of MEDICLIN AG per share		
Undiluted in €	0.32	0.09
Diluted in €	0.32	0.09

Consolidated interim statement of comprehensive income

in €	Jan. – Sept. 2023	Jan. – Sept. 2022
Total consolidated result	15,227,975	4,439,147
Other comprehensive income		
Revaluation from defined benefit plans and similar obligations	2,093,461	22,022,673
Taxes on income	–331,290	–3,485,088
Additions to value adjustments that are not reconciled to the total consolidated result	1,762,171	18,537,585
Thereof attributable to shareholders of MEDICLIN AG	1,748,172	18,411,293
Thereof attributable to non-controlling interests	13,999	126,292
Additions to value adjustments that are reconciled to the total consolidated result	0	0
Group comprehensive income	16,990,146	22,976,732
Thereof attributable to shareholders of MEDICLIN AG	17,022,085	22,761,506
Thereof attributable to non-controlling interests	–31,939	215,226

Consolidated cash flow statement

in €	Jan. – Sept. 2023	Jan. – Sept. 2022
Total consolidated result	15,227,974	4,439,147
Result of finance activities	15,944,068	5,751,875
Result of income taxes	–1,787,248	–103,244
Operating result (EBIT)	29,384,794	10,087,778
Depreciation on fixed asset items	38,860,782	55,094,780
Result before interest, taxes, depreciation and amortisation (EBITDA)	68,245,576	65,182,558
Change in non-current provisions	–1,318,553	249,198
Change in current provisions	234,394	–469,880
Result from the disposal of fixed asset items	–34,521	–86,860
Result from other non-cash items	–6,021,525	–1,817,402
Change in other current assets	–14,718,277	–11,589,552
Change in other non-current liabilities	40,645	52,937
Change in other current liabilities	–1,721,714	–17,390,632
Payments received from interest	1,898,693	577,518
Income taxes paid	3,253,741	–167,869
Cash flow from operating activities	49,858,459	34,540,016
Payments received from the disposal of fixed assets	108,619	206,713
From the disposal of property, plant and equipment	108,619	206,713
Payments received from investment subsidies	17,791,077	14,740,958
Cash used for investments	–24,897,631	–17,475,916
For intangible assets	–2,303,604	–1,131,578
For property, plant and equipment	–22,594,027	–16,344,338
Proceeds from divestments	9,500,000	0
Cash flow from investing activities	2,502,065	–2,528,245
Repayment of lease liabilities	–16,477,585	–34,823,260
Repayment of financial liabilities	–1,236,818	–1,374,510
Interest payments for lease liabilities	–14,368,951	–4,593,186
Other interest payments	–2,060,990	–1,077,188
Cash flow from financing activities	–34,144,344	–41,868,144
Change in consolidation scopes for financial funds	–851,705	0
Cash flow for the period	17,364,475	–9,856,373
Cash and cash equivalents at the beginning of the period	92,277,469	120,052,370
Cash and cash equivalents at the end of the period	109,641,944	110,195,997

Statement of changes in equity

in €	Subscribed capital	Capital reserve	Revenue reserve	Consolidated balance sheet result	Shares MEDICLIN Group	Non-controlling interests	Total equity
As of 01.01.2022	47,500,000	129,391,829	21,418,384	-15,031,793	183,278,420	-254,927	183,023,493
Total consolidated result	-	-	-	4,350,213	4,350,213	88,934	4,439,147
Other comprehensive income	-	-	18,411,293	-	18,411,293	126,292	18,537,585
Group comprehensive income	-	-	18,411,293	4,350,213	22,761,506	215,226	22,976,732
As of 30.09.2022	47,500,000	129,391,829	39,829,677	-10,681,580	206,039,926	-39,701	206,000,225
in €	Subscribed capital	Capital reserve	Revenue reserve	Consolidated balance sheet result	Shares MEDICLIN Group	Non-controlling interests	Total equity
As of 01.01.2023	47,500,000	129,391,829	37,906,157	-5,591,162	209,206,824	115,976	209,322,800
Total consolidated result	-	-	-	15,273,913	15,273,913	-45,938	15,227,975
Other comprehensive income	-	-	1,748,172	-	1,748,172	13,999	1,762,171
Group comprehensive income	-	-	1,748,172	15,273,913	17,022,085	-31,939	16,990,146
Stand 30.09.2023	47,500,000	129,391,829	39,654,329	9,682,751	226,228,909	84,037	226,312,946

Notes

General Information

The unaudited consolidated interim financial statements of MEDICLIN for the first nine months of the 2023 financial year were prepared in accordance with International Accounting Standard 34. The same accounting policies as used in the consolidated financial statements for the 2022 financial year were also applied in this interim report. The interim report should therefore be read in conjunction with the Company's 2022 annual report and the interim reports for the first quarter and the first half-year of 2023.

The discount rate for pension provisions pursuant to IAS 19 amounted to 4.0 % on 30 September 2023 (30.06.2023: 3.6 %; 31.03.2023: 3.5 %, 31.12.2022: 3.6 %).

Quarterly development in the Group

In millions of €	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Sales	182.3	188.1	176.7	178.4	171.0	181.1	174.2
EBITDA	31.2	25.7	11.3	25.7	22.6	27.0	15.6
EBITDA margin in %	17.1	13.7	6.4	14.4	13.2	14.9	8.9
EBIT (operating result)	18.1	13.0	-1.7	9.4	3.5	9.2	-2.6
EBITDA margin in %	9.9	6.9	-0.9	5.3	2.1	5.1	-1.5
Financial result	-5.6	-4.4	-5.9	-3.9	-1.7	-2.0	-2.1
Total consolidated result	10.5	11.0	-6.3	5.3	2.1	6.2	-3.9
Earnings per share in €	0.22	0.23	-0.13	0.11	0.04	0.13	-0.08
Cash flow from operating activities	27.4	4.9	17.6	0.1	25.6	-4.6	13.5
Cash flow from operating activities per share in €	0.58	0.10	0.37	0.01	0.54	-0.10	0.28
Equity ratio in %	24.8	23.6	22.2	22.8	24.5	23.7	21.0
Gross capital expenditure (without right-of-use assets pursuant to IFRS 16)	9.3	8.6	8.1	10.9	8.1	5.7	3.8
Net financial debt ¹ (end of quarter)	8.1	28.4	32.6	34.2	25.3	29.4	34.4
Number of beds (inpatient)	27,560	27,134	26,991	26,321	26,811	26,632	25,052
Number of cases (end of quarter)	8,132	8,132	8,172	8,315	8,315	8,325	8,311
Occupancy rates in %	86.2	84.8	82.4	76.4	79.4	79.6	76.5
Number of full-time employees (quarterly average)	6,960	7,022	7,061	7,059	7,051	6,988	7,003

1 Adjusted net financial debt

Key data on the MEDICLIN SHARE

ISIN: DE 000659 5101; WKN: 659 510; TICKER: MED

In € per share	9M 2023	9M 2022
Earnings, undiluted / diluted	0.32	0.09
Cash flow from operating activities	1.05	0.73
Book value ¹ as of 30.09.	4.76	4.34
Share price as of 30.09.	2.78	3.08
52-weeks high	3.82	–
52-weeks low	2.56	–
Market capitalisation as of 30.09. in millions of €	132.1	146.3
Number of shares in millions	47.5	47.5

¹ Equity less non-controlling interests

Source: Deutsche Börse AG; Xetra / as of 03.07.2023

Financial calendar

29 February 2024

Disclosure of the preliminary figures for the 2023 financial year

26 March 2024

Annual press and analysts' conference for the 2023 financial year

2 May 2024

Publication of the interim report from 1 January 2024 to 31 March 2024

6 June 2024

Annual General Meeting

31 July 2024

Publication of the interim report from 1 January 2024 to 30 June 2024

4 November 2024

Publication of the interim report from 1 January 2024 to 30 September 2024

Adresses and imprint

MEDICLIN Aktiengesellschaft

Okenstraße 27
77652 Offenburg
Telefon +49 (0) 7 81 / 4 88-0
Telefax +49 (0) 7 81 / 4 88-133
E-Mail info@mediclin.de
www.mediclin.de

Public Relations

Daniel Hansmann
Telefon +49 (0) 7 81 / 4 88-260
E-Mail daniel.hansmann@mediclin.de

Investor Relations

Ender Gülcan
Telefon +49 (0) 7 81 / 4 88-326
E-Mail ender.guelcan@mediclin.de

This interim report is also available in German.

This is a translation of the German Interim Report.

In case of divergence from the German version, the German version shall prevail.

